Research Topics
Species | Inder S AnandSummaryAffiliation: University of Minnesota Country: USA Publications
| Collaborators
|
Detail Information
Publications
Surrogate end points in heart failureInder S Anand
University of Minnesota Medical School and Veterans Affairs Medical Center, Minneapolis, Minnesota, USA
J Am Coll Cardiol 39:1414-21. 2002..Other uses of possible surrogates are discussed, and the limitations in finding true surrogates are mentioned. At this time we conclude there is no well established surrogate in HF...- Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) dataSerge Masson
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
Clin Chem 52:1528-38. 2006..This work aimed to provide a direct comparison of the prognostic value of BNP and NT-proBNP in patients with chronic and stable HF... - The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT)Serge Masson
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
J Card Fail 12:375-80. 2006..In this setting, BNP remained the strongest neurohormonal prognostic factor... - Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure TrialInder S Anand
VA Medical Center, Minneapolis, Minnesota, USA
J Am Coll Cardiol 49:32-9. 2007.... - Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trialLidia Staszewsky
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
J Card Fail 13:797-804. 2007..Because little information is available about the population of patients with both syndromes, we assessed the characteristics and the independent contribution of COPD to outcomes in patients with stable chronic heart failure... - Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT)Inder S Anand
VA Medical Center and University of Minnesota, Minneapolis, Minn 55417, USA
Circulation 107:1278-83. 2003..We examined whether changes in brain natriuretic peptide (BNP) and norepinephrine (NE) over time are associated with corresponding changes in mortality and morbidity in the Valsartan Heart Failure Trial... - C-reactive protein in heart failure: prognostic value and the effect of valsartanInder S Anand
VA Medical Center, Minneapolis, MN 55417, USA
Circulation 112:1428-34. 2005..We assessed the prognostic value of CRP in patients randomized in Val-HeFT (Valsartan Heart Failure Trial) and studied changes in CRP that were associated with valsartan... 
Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trialThomas S Rector
Department of Veterans Affairs Health Care System and Department of Medicine, University of Minnesota, Minneapolis, MN 55417, USA
Circ Heart Fail 5:217-25. 2012....- Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFTJay N Cohn
Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55455, USA
J Card Fail 13:331-9. 2007..Whether the fixed-dose combination produces a further regression of LV remodeling when added to renin-angiotensin and sympathetic inhibitors has not been documented... - Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failureInder S Anand
VA Medical Center, Cardiology 111 C, Minneapolis, Minn 55417, USA
Circulation 120:1577-84. 2009..Renin-angiotensin blockade medications improve outcomes in HF but are underutilized in HF patients with renal dysfunction because of safety concerns and a lack of evidence of their effectiveness... - Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure TrialInder S Anand
Cardiology 111 C, VA Medical Center, 1 Veterans Drive, Minneapolis, MN 55417, USA
Circulation 122:1387-95. 2010..Growth-differentiation factor-15 (GDF-15) is emerging as a prognostic biomarker in patients with coronary artery disease. Little is known about GDF-15 as a biomarker in patients with heart failure... - Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFTInder S Anand
VA Medical Center, Minneapolis, MN 55417, USA
Circulation 112:1121-7. 2005..Anemia is known to be a prognostic marker for patients with heart failure. However, little is known about the prognostic value of changes in hemoglobin (Hgb) over time or about the causes of anemia... - Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trialInder S Anand
VA Medical Center and University of Minnesota, Minneapolis, MN 55417, USA
Circ Heart Fail 4:569-77. 2011..Moreover, it is unclear whether treatments have a differential effect on morbidity and mortality across the spectrum of NP levels... 
Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failureInder S Anand
Department of Cardiology, Veterans Administration Medical Center, Minneapolis, MN 55417, USA
Vasc Health Risk Manag 6:449-55. 2010..The safety of once-daily (qd) dosing of valsartan in heart failure (HF) patients is not known...- Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure TrialJay N Cohn
Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, 420 Delaware St SE, Minneapolis, Minn 55455, USA
Circulation 108:1306-9. 2003..The Valsartan Heart Failure Trial (Val-HeFT) provided the first opportunity to examine the long-term effects of an angiotensin receptor blocker on plasma aldosterone levels in patients with NYHA class II through IV heart failure... - Predicting survival in heart failureViorel G Florea
Heart Failure Program, VA Medical Center, One Veterans Drive, 111 C, Minneapolis, MN 55417, USA
Curr Cardiol Rep 9:209-17. 2007..In this review we briefly list established predictive markers and discuss whether survival can accurately be predicted in this condition... - Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure TrialInder S Anand
VA Medical Center, Cardiology, Minneapolis, MN 55417, USA
Circ Heart Fail 1:34-42. 2008..The aim of the present study was to investigate the relationship between the SBP-lowering effects of valsartan and its cardiovascular protective effects in this population... - Carvedilol versus controlled-release metoprolol for elderly veterans with heart failureThomas S Rector
Minneapolis Veterans Affairs Medical Center and Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55417, USA
J Am Geriatr Soc 56:1021-7. 2008..To characterize prescribing of carvedilol and controlled-release (CR) metoprolol for veterans with heart failure who were predominantly elderly (aged > or = 65) and to compare the time to first hospitalization or death... - BiomarkersViorel G Florea
Department of Medicine, University of Minnesota Medical School, 420 Delaware Street Southeast, Minneapolis, MN 55455, USA
Heart Fail Clin 8:207-24. 2012.... - Validation of a risk score for dying within 1 year of an admission for heart failureThomas S Rector
Center for Chronic Disease Outcomes Research, Veterans Administration Medical Center, Minneapolis, Minnesota 55417, USA
J Card Fail 12:276-80. 2006..Mortality in risk score groups was consistent with the original patient cohort. These results support the validity of the risk score and its application to a different patient population... - Relationships between clinical assessments and patients' perceptions of the effects of heart failure on their quality of lifeThomas S Rector
Center for Chronic Disease Outcomes Research, Department of Veterans Affairs Medical Center, 152/2E, One Veterans Drive, Minneapolis, MN 55417, USA
J Card Fail 12:87-92. 2006..Further studies are needed to understand the relationships between heart failure pathology and symptoms and to identify determinants of the effects of heart failure on patients' quality of life that were not related to symptoms... - Critical stenosis of aortic and mitral valves after mediastinal irradiationA Selcuk Adabag
Divisions of Cardiology, Cardiovascular Surgery and Pathology Veterans Affairs Medical Center, Minneapolis, Minnesota 55405, USA
Catheter Cardiovasc Interv 63:247-50. 2004..We present a patient with critical aortic and mitral valve stenosis after mediastinal irradiation and discuss the natural history, treatment, and prognosis of radiation-associated valvular heart disease... - Syndromes of subacute mountain sicknessInder S Anand
Heart Failure Program, VA Medical Center, and University of Minnesota Medical School, Minneapolis, 55417, USA
High Alt Med Biol 5:156-70. 2004..Thus, it appears that both these syndromes are human counterparts of brisket disease in cattle... - Is too much neurohormonal blockade harmful?Inder S Anand
VA Medical Center, One Veterans Drive, 111 C, Minneapolis, MN 55417, USA
Curr Cardiol Rep 6:169-75. 2004..This article reviews some of these studies and analyzes the possible causes of these observations... - The role of arginine vasopressin and its receptors in the normal and failing rat heartY Chandrashekhar
Division of Cardiology, VA Medical Center, University of Minnesota, 1, Veterans Drive, Minneapolis, MN 55425, USA
J Mol Cell Cardiol 35:495-504. 2003..To evaluate the role of arginine vasopressin (AVP) in the normal and post-myocardial infarction (post-MI) hearts, and to investigate whether chronic AVP receptor antagonism can attenuate post-infarct ventricular remodeling... - Anemia and chronic heart failure implications and treatment optionsInder S Anand
Heart Failure Program, VA Medical Center, Mail Stop111C, One Veterans Drive, Minneapolis, Minnesota 55417, USA
J Am Coll Cardiol 52:501-11. 2008.... - Pathogenesis of anemia in cardiorenal diseaseInder S Anand
Veterans Administration Medical Center, University of Minnesota, Minneapolis, Minnesota, USA
Rev Cardiovasc Med 6:S13-21. 2005..Thus, anemia, CHF, and CKD may be independently related to one another, and this relationship may have important implications for their management... - Traditional and novel approaches to management of heart failure: successes and failuresInder S Anand
Division of Cardiology, University of Minnesota Medical School, 420 Delaware Street SE, MMC 508, Minneapolis, MN 55455, USA
Cardiol Clin 26:59-72, vi. 2008.... - Design and performance of a multisensor heart failure monitoring algorithm: results from the multisensor monitoring in congestive heart failure (MUSIC) studyInder S Anand
Veterans Administration Medical Center, Minneapolis, Minnesota, USA
J Card Fail 18:289-95. 2012.... - Pathophysiology of anemia in heart failureInder S Anand
Heart Failure Program, VA Medical Center, 1, Veterans Drive, Minneapolis, MN 55417, USA
Heart Fail Clin 6:279-88. 2010..However, the hemodynamic and neurohormonal alterations could potentially have deleterious long-term consequences and may contribute to anemia's role as an independent risk factor for adverse outcomes... - Heart failure and anemia: mechanisms and pathophysiologyInder S Anand
Department of Medicine, University of Minnesota Medical School, VA Medical Center 111C, Minneapolis, MN 55417, USA
Heart Fail Rev 13:379-86. 2008..However, the hemodynamic and neurohormonal alterations could potentially have deleterious long-term consequences and could contribute to anemia's role as an independent risk factor for adverse outcomes... - Research needed to support clinical use of biomarkers as prognostic indicators for patients with heart failureThomas S Rector
Center for Chronic Disease Outcomes Research, VA Medical Center, One Veterans Drive, Minneapolis, MN 55417, USA
Cardiol Res Pract 2010:453851. 2010..Specific clinical applications need to be identified for informative analyses of data that emphasize the most directly applicable measures of predictive performance... - Noninvasive assessment of left ventricular remodeling: concepts, techniques, and implications for clinical trialsInder S Anand
Division of Cardiology, University of Minnesota Medical School and Veterans Administration Medical Center, Minneapolis, MN 55417, USA
J Card Fail 8:S452-64. 2002..CONCLUSIONS: Each of these techniques carries specific advantages and disadvantages for assessment of remodeling in individual patients and in the context of large-scale clinical trials... - Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: results from the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trialInder S Anand
Division of Cardiology 111 C, Veterans Affairs Medical Center, 1 Veterans Drive, Minneapolis, MN 55417, USA
Circulation 119:969-77. 2009..Because mortality also was significantly reduced (optimal pharmacological therapy versus CRT-D only), an assessment of the true reduction in hospitalization rates must consider the competing risk of death and varying follow-up times... - Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemiaJalal K Ghali
Wayne State University, Detroit, Mich, USA
Circulation 117:526-35. 2008..The Study of Anemia in Heart Failure Trial (STAMINA-HeFT) is the largest multicenter, randomized, double-blind, placebo-controlled trial to date evaluating the effect of treating anemia in HF... - Incremental prognostic value of changes in B-type natriuretic peptide in heart failureRoberto Latini
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
Am J Med 119:70.e23-30. 2006..We hypothesized that B-type natriuretic peptide changes during treatment of heart failure may provide independent information on disease progression and outcome in patients enrolled in the Val-HeFT trial... - Ventricular remodeling in heart failure: a credible surrogate endpointMarvin A Konstam
J Card Fail 9:350-3. 2003 - Effect of left ventricular scar size, location, and transmurality on left ventricular remodeling with healed myocardial infarctionStein Orn
University of Bergen, Stavanger University Hospital, Stavanger, Norway
Am J Cardiol 99:1109-14. 2007..In conclusion, in the studied cohort, there was a linear relation between scar size and ejection fraction and LV volumes. This relation was independent of scar location and transmurality... - Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failureRoberto Latini
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
Circulation 116:1242-9. 2007..We assessed the prognostic value of circulating cardiac troponin T in patients with stable chronic HF with a traditional (cTnT) and a new precommercial highly sensitive assay (hsTnT)... - Chronic heart failure with preserved left ventricular ejection fraction: diagnostic and prognostic value of left atrial sizeAndrea Rossi
Dipartimento di Scienze Biomediche e Chirurgiche, Sezione di Cardiologia Universita degli Studi di Verona, Verona, Italy, and Department of Clinical Cardiology, Royal Brompton Hospital, National Heart and Lung Institute, London, UK
Int J Cardiol 110:386-92. 2006..Data on prognostic markers in such patients are limited. We analyzed the prevalence and prognostic value of left atrial (LA) size in this condition... - Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial)Serge Masson
Department of Cardiovascular Reearch, Istituto Mario Negri, Milan, Italy
J Am Coll Cardiol 52:997-1003. 2008..This study sought to evaluate the association between changes over time of N-terminal pro-brain natriuretic peptide (NT-proBNP) expressed in different ways and outcome in patients with stable and chronic heart failure (HF)...